Allspring Global Investments Holdings LLC Sells 580 Shares of DaVita Inc. (NYSE:DVA)

Allspring Global Investments Holdings LLC decreased its position in shares of DaVita Inc. (NYSE:DVA) by 21.4% during the third quarter, Holdings Channel reports. The institutional investor owned 2,129 shares of the company’s stock after selling 580 shares during the period. Allspring Global Investments Holdings LLC’s holdings in DaVita were worth $349,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Harvard Management Co. Inc. purchased a new position in shares of DaVita during the 2nd quarter valued at $55,115,000. Lazard Asset Management LLC lifted its stake in shares of DaVita by 147.3% during the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock valued at $35,460,000 after buying an additional 153,008 shares in the last quarter. Andra AP fonden lifted its stake in shares of DaVita by 9.0% during the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company’s stock valued at $26,647,000 after buying an additional 15,800 shares in the last quarter. Jupiter Asset Management Ltd. lifted its stake in DaVita by 146.7% in the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after purchasing an additional 111,311 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in DaVita by 1.6% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company’s stock worth $18,612,000 after purchasing an additional 2,129 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 1.3 %

NYSE DVA opened at $141.59 on Friday. DaVita Inc. has a 12 month low of $76.64 and a 12 month high of $168.50. The company’s 50-day moving average price is $157.71 and its 200-day moving average price is $146.05. The stock has a market cap of $11.61 billion, a PE ratio of 15.27, a PEG ratio of 0.79 and a beta of 0.89. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.85 earnings per share. Equities research analysts forecast that DaVita Inc. will post 9.73 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on DVA. Truist Financial boosted their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Bank of America boosted their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. TD Cowen boosted their price target on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. UBS Group boosted their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $161.80.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael David Staffieri sold 9,539 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock worth $27,387,069 in the last ninety days. 2.00% of the stock is owned by company insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.